Phase I-II evaluation of acronine in patients with multiple myeloma.
D000175:Acronine / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000470:Alkaloids / Q000627:therapeutic use*; D000855:Anorexia / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D000470:Alkaloids; D000175:Acronine